Immunis

Irvine, CA · Founded 2019 · Privately Held (backing)

Developer of stem cell-derived therapy designed to treat age and disease-related immune decline. Immunis is based in Irvine, CA and was founded in 2019. Its last known valuation is $75 million. It has raised $37 million across 2 recorded rounds; the latest was a $12 million early-stage round in May 2026.

Last price · $/share
—
Implied valuation
$75.0M
Total raised
$37.0M
Last round
Early Stage VC
May 2026

Who backs Immunis?

12 investors
InvestorType
BOLD Capital PartnersVenture capital
Elevation Capital (Canada)Venture capital
Angel Star Ventures—
Continuum Health Ventures—
Fairfax Financial Holdings—
Healthspan Capital—
JLS Fund—
LifeSpan Vision Ventures—
Remiges Ventures—
Spartan Capital Securities—
+ 2 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Immunis investors

12 investors are on record for Immunis, including BOLD Capital Partners, Elevation Capital (Canada), Angel Star Ventures and Continuum Health Ventures. The early-stage round in May 2026 drew 12 investors.

Free account
More of Immunis with a free account
  • ·The complete investor list: 12 names
  • ·Watch Immunis: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 12 firms already write checks for companies like Immunis. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View